Lupin gets US FDA approval
Analysis based on 16 articles · First reported Jun 26, 2026 · Last updated Jun 27, 2026
The market is positively impacted by the news of Lupin (company)'s tentative FDA approval, as it signifies potential for increased revenue and market share for the company. This could lead to a rise in Lupin (company)'s stock price. For Astellas Pharma, the approval of a bioequivalent generic drug could introduce competition, potentially affecting its market position for Xtandi Tablets.
Lupin (company), a global pharmaceutical company, announced that it has received tentative approval from the United States — Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Enzalutamide Tablets in various strengths (40 mg, 80 mg, 120 mg, and 160 mg). The U.S. FDA found Lupin (company)'s 40 mg and 80 mg Enzalutamide Tablets to be bioequivalent to Astellas Pharma's reference listed drug, Xtandi Tablets. This approval is significant as it provides alternative dosing options for healthcare providers and patients, and expands Lupin (company)'s product portfolio in the U.S. market.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard